ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1692

Using ICD-10-CM Codes to Identify Patients with Systemic Lupus Erythematosus in the Electronic Health Record

April Barnado1, Robert Carroll2, Joshua C. Denny2 and Leslie Crofford1, 1Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, 2Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Electronic Health Record, phenotypes and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, October 22, 2018

Title: Systemic Lupus Erythematosus – Clinical Poster II: Biomarkers and Outcomes

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: The electronic health record (EHR) serves as a powerful tool to enable researchers to collect a large cohort of patients across the healthcare system.  To assemble these patients, algorithms are needed to identify these patients accurately. We have previously validated and published algorithms to identify systemic lupus erythematosus (SLE) subjects in the EHR using ICD-9 billing codes, labs, and keywords. Currently, there are no published algorithms using ICD-10-CM codes. We aimed to develop algorithms using ICD-10-CM codes and clinical data to identify SLE patients accurately in the EHR. Methods: We analyzed data from a de-identified version of Vanderbilt’s EHR that contains over 2.8 million subjects with longitudinal data.  We identified 7399 potential SLE subjects with at least one count of the SLE ICD-9 (710.0) or ICD-10-CM (M32.1*, M32.8, or M32.9) codes.  Of these subjects, we randomly selected 200 as a training set for chart review to identify true case status.  A subject was defined as a case if diagnosed with SLE by a Vanderbilt or external rheumatologist, nephrologist, or dermatologist (specialist).  We selected the following algorithm components based on clinical knowledge and available data: SLE ICD-10-CM codes, positive anti-nuclear antibody (ANA) (titer ≥ 1:160), and ever use of antimalarials. Positive predictive values (PPVs) and sensitivities were calculated for ICD-10-CM codes and combinations of the above algorithm components. Of the 200 subjects, 88 had ICD-10-CM codes with 13 missing clinic notes and excluded from the analysis. Ten subjects had unsure or “probable” SLE diagnoses by a specialist and were not counted as cases.   Results:  Table 1 provides the PPVs and sensitivities of the algorithms. PPVs were higher for algorithms using ICD-10-CM codes compared to those using the ICD-9 code.  Algorithms that used only ICD-10-CM codes without clinical data had PPVs from 71 to 92%.  When adding a positive ANA, PPVs slightly increased and ranged from 69 to 100%. PPVs also slightly increased with adding ever antimalarial use with PPVs from 76 to 95%. The algorithms with the highest PPVs of 100% were 1) ≥ 4 counts of the ICD-10-CM codes and ANA positive and 2) ≥ 4 counts of the ICD-10-CM codes and ANA positive or ever antimalarial use.   Conclusion: Overall, the PPVs for algorithms using ICD-10-CM codes were higher compared to PPVs for ICD-9 codes.  Adding clinical data to ICD-10-CM codes slightly improved the algorithms’ PPVs but may not be required. Since “probable” cases were treated as not cases, PPVs could be underestimated. ICD-10-CM codes can identify SLE cases accurately in the EHR. Studies are underway to investigate the performance of algorithms that combine both ICD-9 and ICD-10-CM codes with clinical data.  

Table 1.

Algorithm

Positive Predictive Value

Sensitivity

ICD-9 codes only

 

 

≥ 1 count of the ICD-9 code (710.0)

58%

100%

≥ 2 counts

69%

78%

≥ 3 counts

77%

67%

≥ 4 counts

79%

60%

ICD-10-CM codes onlya

 

 

≥ 1 count of the ICD-10-CM codes

71%

76%

≥ 2 counts

85%

63%

≥ 3 counts

83%

54%

≥ 4 counts

92%

50%

ICD-10-CM codes AND ANA positiveb

 

 

≥ 1 count of the ICD-10-CM codes AND ANA positive

69%

62%

≥ 2 counts

87%

55%

≥ 3 counts

89%

45%

≥ 4 counts

100%

45%

ICD-10-CM codes AND ever antimalarial use

 

 

≥ 1 count of the ICD-10-CM codes AND ever antimalarial use

76%

70%

≥ 2 counts

90%

57%

≥ 3 counts

88%

50%

≥ 4 counts

95%

46%

ICD-10-CM codes AND ANA positive OR ever antimalarial use

 

 

≥ 1 count of the ICD-10-CM codes AND ANA OR every antimalarial use

68%

72%

≥ 2 counts

86%

62%

≥ 3 counts

82%

48%

≥ 4 counts

100%

48%

aICD-10-CM codes included M32.1*, M32.8, or M32.9 bAnti-nuclear antibody (ANA) positive (≥ 1:160)

 

 


Disclosure: A. Barnado, None; R. Carroll, None; J. C. Denny, None; L. Crofford, None.

To cite this abstract in AMA style:

Barnado A, Carroll R, Denny JC, Crofford L. Using ICD-10-CM Codes to Identify Patients with Systemic Lupus Erythematosus in the Electronic Health Record [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/using-icd-10-cm-codes-to-identify-patients-with-systemic-lupus-erythematosus-in-the-electronic-health-record/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/using-icd-10-cm-codes-to-identify-patients-with-systemic-lupus-erythematosus-in-the-electronic-health-record/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology